Quibim Appoints Itta MacNevin as Chief Business Officer to Accelerate Global Growth and Life Sciences Partnerships
7 April 2026, Valencia – Quibim, the global pioneer in imaging biomarkers for precision medicine, is pleased to announce the appointment of Itta MacNevin as Chief Business Officer (CBO). The appointment marks a significant step in Quibim’s strategy to scale its commercial operations, deepen partnerships across life sciences, and accelerate adoption of its AI-powered imaging solutions globally.
Itta MacNevin brings extensive experience in building and scaling commercial strategies across life sciences, with a strong track record in driving strategic partnerships, revenue growth and international expansion. In her role as Chief Business Officer, she will lead Quibim’s global commercial strategy, overseeing business development, partnerships and go-to-market execution as the company continues to expand its footprint across pharma and biotech.
Quibim’s AI-powered, imaging-based solutions enable pharmaceutical companies to predict which patients will respond to a drug, identify suitable candidates for clinical trials, stratify patients by risk, and accelerate drug development programmes. These capabilities are already driving innovation across oncology, immunology and neurology, positioning Quibim as a critical partner in the shift toward more precise, data-driven medicine.
Ángel Alberich-Bayarri, CEO and Co-Founder of Quibim, said: “Itta’s appointment comes at a pivotal moment for Quibim as we scale our presence in life sciences and expand our global commercial reach. She brings deep expertise in building high-impact partnerships and translating innovative technology into real-world value. Itta will play a central role in strengthening our relationships with pharmaceutical and biotechnology partners and accelerating the next phase of Quibim’s growth.”
Itta MacNevin, Chief Business Officer at Quibim, added: “I’m delighted to be joining Quibim at such an exciting stage in its journey. The company has built a truly differentiated platform at the intersection of AI, imaging and life sciences, with enormous potential to transform how new therapies are developed and delivered. I look forward to working with Ángel and the wider team to scale our commercial strategy, deepen our partnerships across pharma and biotech, and accelerate Quibim’s global impact in precision medicine.”
Itta’s appointment further strengthens Quibim’s leadership team as the company continues to invest in expanding its life sciences capabilities, advancing its oncology ecosystem, and supporting pharmaceutical partners in delivering faster, more efficient and more personalised drug development.
About Quibim
Quibim is a company designing pioneering tools that unlock imaging data to improve patient outcomes. With offices in New York (United States), Cambridge (UK), Valencia, Madrid, and Barcelona (Spain), the company was born from the ambition of turning imaging into a catalyst for precision health. Quibim leads the forefront of imaging biomarkers research in life sciences, pioneering the development of advanced algorithms that transform imaging data into actionable predictions in oncology, immunology and neurology. The company leverages the capabilities of MRI, CT, and PET imaging to create regulatory-cleared Medical Devices that are seamlessly integrated into the workflows of healthcare providers worldwide. More than 150+ sites are using Quibim products globally.